תאריך רישום: March 28, 1993

מסלול הגשה: מולקולה חדשה

יצרן: RECIPHARM KARLSKOGA AB, SWEDEN

בעל רישום: PADAGIS ISRAEL AGENCIES LTD, ISRAEL

N01BB54 :ATC Code

4.1 Therapeutic indications Topical anesthesia for superficial dermal analgesia in connection with insertion of IV catheters, blood sampling and superficial surgical procedures.

תאריך רישום: July 1, 2018

מסלול הגשה: מולקולה חדשה

יצרן: CELLFORCURE, FRANCE

בעל רישום: NOVARTIS ISRAEL LTD

:ATC Code

4.1 Therapeutic indications Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to and including 25 years of age with CD19+ B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse. • Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Limitation of Use: Kymriah is not indicated for treatment of patients with primary or secondary central nervous system lymphoma. • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

תאריך רישום: November 1, 2018

מסלול הגשה: מולקולה חדשה

יצרן: ELI LILLY AND COMPANY, USA

בעל רישום: ELI LILLY ISRAEL LTD, ISRAEL

N02CX08 :ATC Code

4.1 Therapeutic indications Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

תאריך רישום: September 15, 1974

מסלול הגשה: מולקולה חדשה

יצרן: TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

בעל רישום: TEVA ISRAEL LTD

N04BA01 :ATC Code

4.1 Therapeutic indications For the relief of symptoms associated with Parkinson’s disease.

תאריך רישום: June 6, 1999

מסלול הגשה: מולקולה חדשה

יצרן: BAXTER HEALTHCARE S.A., IRELAND

בעל רישום: BAXTER HEALTHCARE DISTRIBUTION LTD., ISRAEL

B05AA05 :ATC Code

4.1 Therapeutic Indications Extraneal is recommended as a once daily replacement for a single glucose 4.4 Special Warnings and Precautions for Use exchange as part of a continuous ambulatory peritoneal dialysis (CAPD) or • Patients with diabetes mellitus often need additional insulin in order to automated peritoneal dialysis (APD) regimen for the treatment of chronic renal maintain glycaemic control during Peritoneal Dialysis (PD). Transfer from failure, particularly for patients who have lost ultrafiltration on glucose solutions, glucose based PD solution to Extraneal may necessitate an adjustment of the because it can extend time on CAPD therapy in such patients. usual insulin dosage. Insulin can be administered intraperitoneally.

תאריך רישום: May 2, 2007

מסלול הגשה: מולקולה חדשה

יצרן: BAUSCH & LOMB INCORPORATED, USA

בעל רישום: TEVA ISRAEL LTD

S01BA14 :ATC Code